Top biopharma company selects the next generation
of CRM for life sciences as its commercial foundation for
future expansion and launches
PLEASANTON, Calif., Nov. 14,
2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today
announced that Boehringer Ingelheim is the latest global top 20
biopharma company to commit to moving to Veeva Vault CRM.
"We are excited to bring our innovative research to patients
around the world with up to 25 new treatment launches by 2030.
Veeva has been our global CRM standard for many years, and we are
eager to build on our successful partnership and help shape the
future of life sciences with a commitment to move to Veeva Vault
CRM," said Uday Bose, head of human
pharma global customer experience excellence and business steering
at Boehringer Ingelheim. "Our goal to deliver outstanding customer
experiences is shared with Veeva and our continued collaboration
promises to help transform commercial operations to accelerate
launch processes and drive highly personalized engagement."
Boehringer Ingelheim is seeking to expand on its existing Veeva
Commercial Cloud solutions and its One
Medicine and Amplify platforms, which connect development
processes and data on Veeva Development Cloud.
"Boehringer Ingelheim has a forward-looking approach to unifying
its technology and data landscape to rapidly deliver therapies that
improve human and animal health," said Tom
Schwenger, president and chief customer officer at Veeva. "I
am thrilled to see our long-standing partnership expand with their
move to Veeva Vault CRM."
Boehringer Ingelheim will join the opening keynote at Veeva
Commercial Summit Europe, sharing how Vault CRM is a key enabler of
future commercial agility, innovation, and differentiation.
Additional Information
For more on Veeva Vault CRM,
visit: veeva.com/VaultCRM
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's
products and services and the expected results or benefits from use
of our products and services. These statements are based on our
current expectations. Actual results could differ materially from
those provided in this release and we have no obligation to update
such statements. There are numerous risks that have the potential
to negatively impact our results, including the risks and
uncertainties disclosed in our filing on Form 10-Q for the period
ended July 31, 2024, which you can
find here (a summary of risks which may impact our
business can be found on pages 36 and 37), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-commits-to-veeva-vault-crm-302305119.html
SOURCE Veeva Systems
